Discovery, Synthesis, SAR Development of a Series of *N*-4-(2,5-dioxopyrrolidin-1-yl)-phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu₄) with Oral Efficacy in an anti-Parkinsonian Animal Model

Carrie K. Jones[†,‡,#], **Darren W. Engers**[†,‡,▼], **Analisa D. Thompson**[†,‡], **Julie R. Field**[†], **Anna L. Blobaum**[†,‡], **Stacey R. Lindsley**[†,‡], **Ya Zhou**[†,‡], **Rocco D. Gogliotti**[†,‡], **Satyawan Jadhav**[†,‡], **Rocio Zamorano**[†,‡], **Jim Bogenpohl**[§], **Yoland Smith**[§], **Ryan Morrison**[†,‡], **J. Scott Daniels**[†,‡], **C. David Weaver**[†,∞], **P. Jeffrey Conn**[†,‡,∞,▼], **Craig W. Lindsley**[†,‖,‡,∞,▼], **Colleen M. Niswender**[*,†,‡], and **Corey R. Hopkins**[*,†,‖,‡,▼]

[†]Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232

[‡]Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232

[#]Tennessee Valley Healthcare System, U.S. Department of Veterans Affairs, Nashville, TN, 37212, USA

[‖]Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232

[∞]Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232

[▼]Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (MLPCN), Nashville, Tennessee, 37232, United States

[§]Yerkes National Primate Research Center and Department of Neurology, Emory University, Atlanta, GA 30329, USA

Abstract

There is an increasing amount of literature data showing the positive effects on preclinical anti-Parkinsonian rodent models with selective positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu₄).1 However, most of the data generated utilize compounds that have not been optimized for drug-like properties and, as a consequence, they exhibit poor pharmacokinetic properties and thus do not cross the blood-brain barrier. Herein, we report on a series of *N*-4-(2,5-dioxopyrrolidin-1-yl)-phenylpicolinamides with improved PK properties with

---

[1]Abbreviations: SAR: structure-activity relationship; mGluR: metabotropic glutamate receptor; PAM: positive allosteric modulator; HTS: high-throughput screening; Clint: intrinsic clearance; PPB: plasma protein binding; AUC: area under the curve; GPCR: G-protein coupled receptor; **1**: *N*-phenyl-7-(hydroxyimino)cyclopropa[*b*]chromen-1a-carboxamide; CNS: central nervous system; PD: Parkinson's disease; GIRK: G protein-coupled inwardly-rectifying potassium channel; CYP: cytochrome P450; TPSA: topological polar surface area; CL$_{HEP}$: predicted hepatic clearance; B/P: brain:plasma ratio; CRC: concentration-response curve; %fu: percent free, unbound; DA: dopamine; PK: pharmacokinetics; BBB: blood-brain barrier; MW: molecular weight; FS: fold shift; RLM: rat liver microsomes.

[*]To whom correspondence should be addressed. Phone: 615-343-4303. Fax: 615-343-3088. colleen.niswender@vanderbilt.edu (CMN). Phone: 615-936-6892. Fax: 615-936-4381. corey.r.hopkins@vanderbilt.edu (CRH).

excellent potency and selectivity as well as improved brain exposure in rodents. Finally, ML182 was shown to be orally active in the haloperidol induced catalepsy model, a well-established anti-Parkinsonian model.

Keywords

metabotropic glutamate receptors; mGlu$_4$; positive allosteric modulators; Parkinson's disease; haloperidol-induced catalepsy; structure-activity relationship (SAR); oral efficacy; brain penetration

Introduction

Parkinson's disease (PD) is a neurodegenerative disease that affects the central nervous system and is present in nearly 1 in 300 adults.[1] With the exception of Alzheimer's disease (AD), PD is the most common neurodegenerative disorder. PD is part of a larger group of conditions known as movement disorders and is characterized by four major primary symptoms: tremor, which is present at rest; bradykinesia, loss of spontaneous movement; rigidity, an increase in muscle tone; and disturbance of posture, an inability to maintain an upright posture.[1–4] The major motor disturbances in PD patients are due to the loss of mesencephalic dopaminergic neurons in the substantia nigra which results in the decreased stimulation of the motor cortex by the basal ganglia. In addition to the more prominent motor disturbances, PD patients also suffer from significant non-motor symptoms, such as depression, sleep disorders, and cognitive problems.[1–6] Although the disease was first noted in the medical community nearly 200 years ago[7], there is still no known cure for PD – and, as important, there are very few palliative drugs that provide benefit over the time frame of the disease progression.

Due to the discovery that the loss of dopaminergic neurons is the primary culprit for the motor disturbances in PD patients, the development of dopamine (DA) replacement therapies have dominated the PD treatment landscape.[8] The primary pharmaceutical used for the treatment of PD is levodopa (L-DOPA) – since the use of dopamine itself proved ineffective since it does not cross the blood-brain barrier (BBB). However, it was also discovered that the use of L-DOPA as a stand-alone treatment proved very difficult due to the rapid decarboxylation of L-DOPA which releases vasoactive DA prior to crossing the BBB, resulting in severe cardiovascular events. This side effect can be mitigated by the co-administration of an amino acid decarboxylase inhibitor which significantly increases the levels of DA in the CNS without the cardiovascular side effects.[3, 4] Several other direct-acting DA agonists have been introduced, as well other therapies for increasing DA levels. Although the introduction of L-DOPA has significantly improved the initial treatment of PD, DA-replacement therapies have significant complications with long-term use. For example, a 'wearing-off' and 'on-off' phenomenon has been noted in which DA-replacement therapies lose efficacy over time, resulting in an ever-increasing dosage cycle.[9, 10] Other consequences of DA-replacement include dyskinesias (rocking movements, repetitive motor behaviors) and psychotic and behavioral disturbances that often develop after long-term usage.[11] Due to these significant side-effects of DA-replacement, alternative approaches towards the treatment and reversal of PD have been investigated, including invasive surgery and deep brain stimulation (DBS), along with attempts to develop agents to manipulate other, potentially druggable targets (e.g., antagonists of A$_{2A}$ adenosine receptors). Due to the limitations of current therapies for PD, we became interested in a potentially new target for the palliative care, and potential disease-modification, of PD. Due to exceptionally high expression levels of metabotropic glutamate receptor 4 (mGlu$_4$) at the

striatopallidal synapse of the basal ganglia, we and others have targeted this receptor for therapeutic intervention into PD.[12–17]

Over the past several years, our laboratories and others have added to the list of selective and novel tool compounds for the study of mGlu$_4$ via positive allosteric modulation (Figure 1). Thus far, three disclosed mGlu$_4$ PAMs (2[18], 3[19] and 4[20]) have been shown to be CNS penetrant when dosed systemically, with compound **4** exhibiting efficacy in the haloperidol-induced catalepsy assay.[21] In addition to the aforementioned *in vivo* tool compounds, there have been numerous *in vitro* tools reported.[22–24]

Compound **3** possesses an acceptable balance of *in vitro* pharmacological properties, as well as moderate stability in rat liver microsomes (RLM). While compound **3** was able to cross the blood-brain barrier with an acceptable brain:plasma ratio (B/P = 1), its overall brain penetration was substantially reduced compared to the aminopyridine, **4**. In this study, we disclose a series of *N*-4-(2,5-dioxopyrrolidin-1-yl)-phenylpicolinamide mGlu$_4$ positive allosteric modulators that are CNS penetrant and show oral efficacy in an anti-Parkinsonian animal model.

Results and Discussion

Although we have reported on several mGlu$_4$ *in vitro* and *in vivo* tool compounds, there still remains room for significant improvement in an acceptable probe for the mGlu$_4$ receptor. To this end, we started from a functional high-throughput screening (HTS) initiated at Vanderbilt University, and discovered an interesting new lead compound, *N*-(4-(1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazol-2-yl)phenyl)furan-2-carboxamide, **8** (Figure 2, Pubchem Compound ID (CID): 4066845; ChemDiv ID: K906-0087). Although compound **8** did not possess favorable calculated properties for a CNS probe compound (MW = 404.4, TPSA = 109.9), it represented a submicromolar starting point for our mGlu$_4$ hit-to-lead program.

The 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazol-2-yl)phenyl)carboxamide compounds were synthesized as outlined in Scheme 1. Commercially available mono-Boc protected 1,4-dianiline, **5**, was reacted with 1,2-dibenzenedisulfonyl dichloride (Et$_3$N, CH$_2$Cl$_2$) yielding **6**. Next, the Boc group was removed under acidic conditions (4.0 M HCl/dioxane) and then the amides, **8a–l**, were formed utilizing either the carboxylic acids (EDCI, HOBt, dioxane/DMF) or acid chlorides (DIEA, CH$_2$Cl$_2$).

The structure-activity relationship (SAR) surrounding this set of compounds mirrored other series that we have reported previously (Table 1).[18, 19, 24] Namely, the 2-pyridyl amide, **8d**, was the most potent heterocyclic substituent (hEC$_{50}$ = 136 nM). Other aryl, cycloalkyl and 5-membered heterocycles also showed submicromolar potency at both the human and rat mGlu$_4$ receptors. However, despite these modifications, the molecular weight (MW) and polar surface area (TPSA) remained suboptimal for the design of a CNS penetrant probe compound. To confirm this prediction, we profiled **8d** in both *in vitro* and *in vivo* rat pharmacokinetic (PK) experiments and assessed the extent of CNS penetration for this compound (Table 2). While the compound displayed selectivity against other mGlu subtypes (mGlu$_{1–3,5,6–8}$), the extent of brain penetration was poor (B/P = 0.085) following intraperitoneal (IP) administration to rats..

Next, we turned our attention to compounds that would have more favorable calculated properties for a CNS penetrant molecule (MW < 400, TPSA < 90) (Table 3). To this end we examined the effect of removing the carbonyl of the amide was evaluated. Subsequent replacement of the carbonyl with a methylene group (**9b**) or a cyclopropyl group (**9c**) effectively reduced the TPSA (113 to 96) of the scaffold, however with a cost of 10- to 40-fold reduction in mGlu$_4$ potency. Likewise, the addition of a substituent *ortho* to the amide

on the internal phenyl group (**9a**), or reversing the amide (**9d**), proved to alter the TPSA but, again, with a significant reduction in the potency for both compounds.

One area of diversification where we have had success with other series is the 4-position of the internal phenyl group. Therefore, we evaluated the activity of a number of substitutions similar to the 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazol-2-yl group, in an attempt to reduce TPSA and, ultimately, improve brain penetration. The inclusion of an imide group in lieu of the 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazol-2-yl moiety represented a net lowering of the MW by 60 Da and the TPSA by approximately 30 Å^2. The synthesis of the imide compounds is shown in Scheme 2.

Evaluation of the compound containing a sultam group revealed a complete loss of activity (**16**) (Table 4). This core phenyl group does not contain a halogen as do the other compounds; however, the compound containing an internal halogen was not attainable by synthesis. Next, a series of imide compounds were investigated. The initial five-membered imide compound was active (**15a**, hEC_{50} = 6200 nM), however the compound lost ~20-fold activity compared to **8d**. Potency could be recovered by increasing the bulk of the right-hand side by utilizing phthalimide (and substituted phthalimides) (**15b**, hEC_{50} = 59.4 nM; **15c**, hEC_{50} = 42 nM). However, an initial metabolic stability assessment revealed these compounds suffered from extensive oxidative metabolism (results not shown). Having demonstrated the phenyl moiety of the phthalimide as the predominant metabolic soft spot, we turned to saturated versions of the phthalimide (**15d – 15l**). The initial compound was the direct saturated comparator to **15b** (**15d**, hEC_{50} = 370 nM). Although there was a ~10-fold loss of potency, **15d** still showed <500 nM potency against hmGlu4. The *trans*-isomer was also evaluated with similar potency to the *cis*-**15d** (results not shown). Increasing the bulk of the saturated six-membered ring resulted in interesting compounds. The [2.2.1]-bridged oxo compound (**15e**, hEC_{50} = 1300 nM) exhibited a 4-fold loss in potency; however the unsaturated [2.2.1]-bridged carbon analog (**15f**, hEC_{50} = 291 nM) and unsaturated [2.2.2]-analog (**15g**, hEC_{50} = 287 nM) were more potent than **15d**. Reducing the ring size from 6-membered to a substituted 3-membered ring resulted in an equipotent compound (**15h**, hEC_{50} = 435 nM). Substitution of the 5-membered imide led to a loss of activity (**15i**, hEC_{50} = 1400 nM), but remained comparable to the initial 5-membered imide (**15a**). However, when the size of the substituent was increased from the *gem*-dimethyl to cyclohexyl (**15j**, hEC_{50} = 158 nM) there was a 10-fold increase in activity. Other bulky substituents were evaluated (**15k**, hEC_{50} = 674 nM; **15l**, hEC_{50} = 771 nM); however, these compounds lost activity when compared to **15f**.

With our best compounds evaluated for human potency, we evaluated the in vitro potency of the compounds on the rat mGlu4 receptor. Additionally, we compared compounds in terms of their relative efficacy which we evaluated by assessing the ability of a 30 µM concentration of each compound to shift a glutamate concentration-response curve to the left (represented as fold shift, FS) (Table 5). For examination of compound activity at the rat receptor, we employ an assay in which we measure the ability of the $G_{i/o}$-coupled $mGlu_4$ receptor to couple to G Protein Inwardly Rectifying Potassium (GIRK) channels.[25] In contrast to the calcium mobilization assay, we generally do not observe large increases above the response elicited by saturating concentrations of glutamate alone when GIRK activation is used to assess activity; rather, compounds shift the glutamate concentration-response curve to the left only. Compounds from the 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazol-2-yl)phenyl)carboxamide series (**8d–8k**) all possessed GluMax values comparable to that of **1** and their efficacies in shifting the glutamate curve were modest, between 3.3 and 7.3. However, moving from the 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazol-2-yl)phenyl)carboxamide series to the imide series produced significant divergence in compound efficacies. In particular, two phthalimide compounds (**15b** and **15c**)

exhibited large differences in efficacy (leftward fold shift values of 23.6 and 83.0, respectively). Compound **15c** produced the largest leftward shift of the glutamate response curve reported to date. It is also noted that moving away from the phthalimide structures to the saturated imides led to a significant reduction in efficacy and the largest fold shift value for the saturated compounds was 16.7 (**15l**), with most of the compounds tested exhibiting fold shifts of <10 (See Supplemental Figure 1 for graphs of human and rat potency and fold shift experiments). The exceptions were **15f** (11.2), **15k** (12.1) and **15l** (16.7).

Having identified several key compounds based on human and rat potency as well as efficacy at the rat receptor, we evaluated these compounds in a battery of pharmacokinetic assays including an assessment of intrinsic clearance (CL_{int}) in hepatic microsomes. In addition to intrinsic clearance allowing for the prediction of pertinent rat and human PK parameters (CL and $t_{1/2}$), intrinsic clearance assessments allow for a rank ordering of compounds with respect to oxidative lability and a subsequent predicted stability in our *in vivo* PK and efficacy models (Table 6). Although two compounds based on the phthalimide scaffold (**15b** and **15c**) showed excellent *in vitro* potency on mGlu$_4$, these compounds have been previously reported by Merck and thus were not further evaluated.[26] The three compounds based on the saturated imide scaffold (**15f, 15j–k**) displayed elevated clearance in human liver microsomes, each exceeding hepatic blood flow in humans (Q_H, 21 mL/min/kg). Conversely, an assessment in RLM indicated the compounds to possess moderate-to-high predicted hepatic clearance (CL_{HEP}), with compound **15k** predicting the best stability in rat (CL_{HEP} = 30 mL/min/kg). Assessment of the compound's affinity for plasma proteins was also estimated (percent free, unbound; %fu) in vitro in cryopreserved plasma (Table 6). While compounds **15j** and **15k** were highly protein bound in both human and rat plasma (%fu <1), **15f** displayed lower protein binding under the same conditions (%fu >3). In addition, **15f** was also investigated for nonspecific binding (NSB) in freshly prepared rat brain homogenate employing rapid equilibrium dialysis and found to display a decrease in NSB (%fu >7%) relative to binding to plasma proteins. As a first-tier screen for potential drug-drug interaction liability, the compounds were evaluated for their inhibition of the cytochrome P450 (CYP450 or CYP) enzymes utilizing a cocktail approach in human liver microsomes designed to inform on the inhibition of the five major drug-metabolizing and/or polymorphic CYPs (CYP2C9, 2D6, 3A4, 2C19, and 1A2). All compounds tested showed no significant activity against CYP2D6 and CYP3A4 (>30 µM); and only **15k** showed moderate inhibition of 2C9, 2C19 and 1A2 (8.7 µM, 17.6 µM, and 8.9 µM, respectively).

Lastly, these compounds were evaluated for their selectivity against the other mGlu receptors. For initial studies, a 10 µM concentration of compound was applied prior to a complete agonist concentration-response curve (CRC) appropriate for each receptor. This technique allows for the detection of potentiator (leftward shift) or antagonist (rightward shift and/or decrease in the maximal response) activity within a single experiment. Using this assay, all compounds were selective versus the Group II mGlus (2 and 3) and only **15f** showed weak PAM activity against a group I receptor (mGlu$_5$, 2.1 FS). However, these compounds did show varying selectivity against the other Group III receptors. Whereas **15j** only showed weak activity against mGlu$_6$ (PAM, 2.1 leftward FS of the agonist CRC), **15f** was weakly active against both mGlu$_6$ (PAM, 3.1 FS) and mGlu$_7$ (PAM, 2.9 FS), and **15k** showed activity against all 3 receptors (mGlu$_6$, PAM, 5.8 FS; mGlu$_7$, mixed agonist/PAM (Ago-PAM) activity, 12.9 FS; mGlu$_8$, PAM, 2.1 FS); the allosteric agonist activity against mGlu$_7$ was equivalent to that observed for mGlu$_4$ (12.9 FS vs. 12.1 FS).

The predicted *in vitro* ADME properties of these compounds were consistent with advancement for *in vivo* studies. Thus, the hydrochlorides of these compounds (**15f, 15j, 15k**) were synthesized and dosed intravenously (1 mg/kg) and orally (10 mg/kg) to determine pertinent PK parameters such as clearance (CL), volume-of-distribution at steady

state (Vss), half-life ($t_{1/2}$) as well as bioavailability (%F) (Table 7). Although all three compounds displayed modest stability (CL_{HEP}) when assessed in rat liver microsomes; **15k** proved to be a lower clearance compound in vivo (5.4 mL/min/kg). Both **15f** and **15j** demonstrated moderate clearance values (37 mL/min/kg and 48 mL/min/kg, respectively), values that correlated well with their *in vitro* CL_{HEP} values. Due to the exceptional stability of **15k** following parenteral administration to the rat, we evaluated this compound in both beagle dog and rhesus monkey employing an IV cassette dosing paradigm. Compound **15k** showed excellent stability in both dogs (CL, 7 mL/min/kg) and monkeys (3 mL/min/kg) with each species diplaying a $t_{1/2}$ of $\geq$ 3 hrs. Although **15k** showed superior stability comparatively, it unfortunately displayed an oral bioavailability less than 10%; Conversely, compound **15f** demonstrated an excellent oral bioavailability of 97% whereas **15j** displayed a modest bioavailability of 25%.

The combination of enhanced bioavailability, oral PK, in addition to an exceptionally low protein binding value, indicated that compound **15f** possessed the characteristics to be a potential tool compound which could be evaluated for brain exposure after oral dosing (Table 8). The hydrochloride salt of **15f** was dosed orally in a microsuspension (10% Tween-80 in 0.5% methylcellulose) and plasma (systemic and hepatic portal) and brain samples were collected for bioanalysis of parent compound up to 6 hours following administration of the compound. The compound showed similar levels in the systemic and HPV plasma, indicating neglible hepatic first pass metabolism (AUC_{SYS}/AUC_{HPV} = 1.01). Compound **15f** also displayed exceptional CNS penetration, with compound exposures reaching 800 nM*h (AUC_{0-6}) and a corresponding brain:plasma ratio that reached unity (0.93).

Considering the promising PK results for **15f**, we evaluated the compound for selectivity against the other mGlu subtypes. In these studies, a 10 point concentration-response of **15f** was applied prior to an EC_{20} concentration of agonist appropriate for each receptor. As with our original fold shift-type studies, **15f** was shown to be inactive against mGlu 1, 2, 3, and 8 and was active against $mGlu_5$ (PAM, EC_{50} = 1.7±0.8 µM, 64.3±0.8% GluMax), $mGlu_6$ (PAM, EC_{50}>10 µM, 45.8±3.0% GluMax) and $mGlu_7$ (PAM, 2.9±0.7 µM, 64.0±1.4% GluMax) (See Supplemental Table 1). In addition, **15f** was tested in Ricerca's Lead Profiling Screen (binding assay panel of 68 GPCRs, ion channels and transporters screened at 10 µM), and was found to not significantly with all the 68 assays conducted (no inhibition of radioligand binding > 50% at 10 µM).

Based on the previous PK studies, **15f** was chosen as a potential tool compound for an *in vivo* proof-of-concept study and was examined in a rat model of neuroleptic-induced catalepsy. Here we evaluated the ability of **15f** to reverse haloperidol-induced catalepsy, a preclinical rodent model of motor impairments associated with Parkinson's disease. The D_2 receptor antagonist haloperidol induced robust catalepsy (Figure 10). As shown in Figure 10, **15f** (0.1 – 56.6 mg/kg, p.o.) produced a reversal of haloperidol-induced catalepsy ($F_{(8,89)}$= 5.8697, p<0.0001), significant at doses of 0.1 – 56.6 mg/kg, as compared with the vehicle control. The effects of **15f** were equally efficacious to those observed using an adenosine A_{2A} antagonist from Neurocrine Bioscience (compound **23**)[27] as a positive control, administered at a dose of 56.6 mg/kg, po.

Conclusion

In summary, we have discovered and characterized a new $mGlu_4$ PAM *in vivo* tool compound with activity in a preclinical model of Parkinson's disease. This new class of *N*-4-(2,5-dioxopyrrolidin-1-yl)-phenylpicolinamides (such as **15f**, VU0400195 (ML182))[28] was discovered utilizing a rational drug design approach based on the 1,1,3,3-tetraoxidobenzo[d]

[1,3,2]dithiazol-2-yl)phenyl)carboxamides (**8d**) scaffold that possessed suboptimal properties. A common feature in many of the reported mGlu$_4$ PAMs is the presence of a picolinamide moiety which this new scaffold also possesses. However, these new compounds are structurally distinct from previously reported structures due to the presence of the 2,5-dioxopyrrolidin-1-yl moiety. The present report represents only the second example of a potent and selective, orally active mGlu$_4$ PAM.[20]

Experimental Section

General

All NMR spectra were recorded on a 400 MHz AMX Bruker NMR spectrometer. [1]H chemical shifts are reported in δ values in ppm downfield with the deuterated solvent as the internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), integration, coupling constant (Hz). Low resolution mass spectra were obtained on an Agilent 1200 series 6130 mass spectrometer with electrospray ionization. High resolution mass spectra were recorded on a Waters Q-TOF API-US plus Acquity system with electrospray ionization. Analytical thin layer chromatography was performed on EM Reagent 0.25 mm silica gel 60-F plates. All samples were of ≥95% purity as analyzed by LC-UV/Vis-MS. Analytical HPLC was performed on an Agilent 1200 series with UV detection at 214 nm and 254 nm along with ELSD detection. LC/MS: Method 1 = (J-Sphere80-C18, 3.0 × 50 mm, 4.1 min gradient, 5%[0.05%TFA/CH$_3$CN]:95%[0.05%TFA/H$_2$O] to 100%[0.05%TFA/CH$_3$CN]; Method 2 = (Phenomenex-C18, 2.1 X 30 mm, 2 min gradient, 7%[0.1%TFA/CH$_3$CN]:93%[0.1%TFA/H$_2$O] to 100%[0.1%TFA/CH$_3$CN]; Method 3 = (Phenomenex-C18, 2.1 X 30 mm, 1 min gradient, 7%[0.1%TFA/CH$_3$CN]:93%[0.1%TFA/H$_2$O] to 95%[0.1%TFA/CH$_3$CN]. Preparative purification was performed on a custom HP1100 purification system (reference 16) with collection triggered by mass detection. Solvents for extraction, washing and chromatography were HPLC grade. All reagents were purchased from Aldrich Chemical Co. and were used without purification.

tert-Butyl (4-(1,1,3,3-tetraoxidobenzo[*d*][1,3,2]dithiazol-2-yl)phenyl)carbamate (6)

A solution of *N*-Boc-*p*-phenylenediamine, **5**, (0.68 g, 3.26 mmol, 1.0 equivalents) and Et$_3$N (0.51 mL, 7.19 mmol, 2.2 equivalents) in dry DCM (29 mL) was added via syringe pump (8 mL/ h) to a refluxing solution of 1,2-benzenedisulfonyl dichloride (0.90 g, 3.27 mmol, 1.005 equivalents) in DCM (135 mL). After the complete addition, the reaction solution was maintained at reflux for an additional 2 h. The heat was removed and after 16 h at rt, the solvent was removed under reduced pressure. The residue of the crude reaction mixture was redissolved in DCM (75 mL) and washed with saturated NaHCO$_3$ (aq, 75 mL), brine (75 mL), and dried (MgSO$_4$). After the filtration and concentration under reduced pressure, analytical LCMS confirms product (**6**). The material was taken through to the deprotection step. ^{1}H NMR (400 MHz, CDCl$_3$): δ 8.11-8.08 (m, 2 H), 7.99-7.96 (m, 2 H), 7.59-7.55 (m, 4 H), 6.66 (br s, 1 H), 1.54 (s, 9 H).

2-(4-Aminophenyl)benzo[d][1,3,2]dithiazole 1,1,3,3-tetraoxide (7)

To a solution of **6** (3.26 mmol, 1.0 equivalents) in DCM (100 mL) at 0 °C was added dropwise 4N HCl in dioxane (20 mL). After 15 min, the ice bath was removed. Once the starting material was no longer evident by TLC, the solvent was removed affording the HCl salt (**7**), which were taken through to the amide formation step. LCMS: R$_T$ = 3.319 min, *m/z* = 311.0 [M + H]$^+$. ^{1}H NMR (400 MHz, DMSO-*d$_6$*) ° 8.55-8.51 (m, 2 H), 8.21-8.17 (m, 2 H), 7.17-7.15 (m, 2 H), 6.75-6.73 (m, 2 H).

N-(4-(1,1,3,3-Tetraoxidobenzo[d][1,3,2]dithiazol-2-yl)phenyl)picolinamide (8d)

To a solution of the HCl salt (**7**) (1.0 equivalent) in DCM:DIEA (4:1) (1 mL, 0.1 M) was added picolinyl acid chloride (1.0 equivalent) was added and after 12 h at rt, the desired analog, **8d**, was obtained as an tan solid (49%). Analytical LCMS: R_T = 3.074 min, >98% (214 nm), m/z = 416.1 [M + H]$^+$; ^{1}H NMR (400 MHz, d_6-DMSO): δ 11.08 (br s, 1 H), 8.79 (d, 1 H, J = 4.0 Hz), 8.60-8.59 (m, 2 H), 8.24-8.21 (m, 5 H), 8.11 (t, 1 H, J = 8.0 Hz), 7.73 (t, 1 H, J = 4.8 Hz), 7.59 (d, 2 H, J = 8.4 Hz); ^{13}C NMR (125 MHz, d-DMSO-d_6) δ 163.5, 149.8, 148.9, 142.1, 138.7, 136.8, 134.0, 133.0, 127.7, 123.8, 123.1, 122.4, 119.1. HRMS, calc'd for $C_{18}H_{13}N_3O_5NaS_2$ [M + Na$^+$], 438.0194; found 438.0194.

Bis(*tert*-butyl-2-chloro-4-nitrophenyl)carbamate (11)

To a solution of 2-chloro-4-nitroaniline, **10**, (5.0 g, 29 mmol) and DMAP (50 mg, 0.41 mmol) in dry THF (250 mL) was added Boc$_2$O (16.0 g, 73.3 mmol). The mixture was heated to reflux. After 1h, the solvent was removed. The residue was redissolved in EtOAc: 0.5 N HCl (aqueous) and the organic layer was separated. The aqueous layer was extracted with EtOAc (3 × 50 mL) and the collected organic layers were washed with Brine (100 mL). The solution was dried (MgSO$_4$), filtered and concentrated to afford bis(*tert*-butyl-2-chloro-4-nitrophenyl)carbamate, **11**. LCMS: R_T = 3.74 min., >98% @ 254 nM, m/z = 767.2 [2M + Na]$^+$.

Bis(*tert*-butyl-4-amino-2-chlorophenyl)carbamate (12)

To a solution of bis(*tert*-butyl-2-chloro-4-nitrophenyl)carbamate, **11**, (29.0 mmol) in EtOAc (120 mL) was added 5% Pd/C (150 mg) and an H$_2$ atmosphere was applied. After 12 h, TLC confirmed loss of starting material. The reaction mixture was filtered through Celite and concentrated to afford bis(*tert*-butyl-4-amino-2-chlorophenyl)carbamate which was used without further purification. ^{1}H NMR (400 MHz, CDCl$_3$) δ 6.94 (d, 1 H, J = 8.4 Hz), 6.72 (d, 1 H, J = 2.8 Hz), 6.53 (dd, 1 H, J = 8.4, 2.8 Hz), 3.75 (br s, 2 H), 1.41 (s, 18 H).

Bis(*tert*-butyl 2-chloro-4-(picolinamido)phenyl)carbamate (13)

A solution of bis(*tert*-butyl-4-amino-2-chlorophenyl)carbamate, **12**, (29.0 mmol) in DCM (25 mL) at 0 °C was subjected to DIEA (10.2 mL, 72.5 mmol) followed by picolinoyl chloride hydrochloride (5.68 g, 31.9 mmol). After 12 h, the reaction was added to EtOAc:H$_2$O (1:1, 120 mL). The organic layer was washed with water (2 × 50 mL), brine (50 mL) and dried (MgSO4). The mixture was filtered and concentrated to provide bis(*tert*-butyl 2-chloro-4-(picolinamido)phenyl)carbamate, **13**. ^{1}H NMR (400 MHz, CDCl$_3$) δ 10.17 (br s, 1 H), 8.63 (d, 1 H, J = 4.0 Hz), 8.32 (d, 1 H, J = 8.0), 8.05 (d, 1 H, J = 2.4 Hz), 7.96 (ddd, 1 H, J = 8.0, 8.0, 1.2), 7.66 (dd, 1 H, J = 8.4, 2.4), 7.55-7.52 (m, 1 H), 7.20 (d, 1 H, J = 8.8 Hz), 1.40 (s, 18 H).

N-(4-Amino-3-chlorophenyl)picolinamide (14)

To a solution of bis(*tert*-butyl 2-chloro-4-(picolinamido)phenyl)carbamate, **13**, (29.0 mmol) in DCM (300 mL) at 0 °C was added dropwise 4N HCl in dioxane (50 mL). After 15 min, the ice bath was removed. Once the starting material was no longer evident by TLC, the solvent was removed affording the HCl salt. The crude material was redissolved with EtOAc (100 mL) and washed with NaHCO$_3$ (aqueous). The organic layer was dried (MgSO4), filtered and concentrated to afford N-(4-amino-3-chlorophenyl)picolinamide, **14**. LCMS: R_T = 1.15 min., >98% @ 254 nM, m/z = 248.0 [M + H]$^+$.

General Cyclic Imide formation

To a solution of N-(4-amino-3-chlorophenyl)picolinamide, **14**, (1.0 equivalent) in toluene:acetic acid (3:1) was added desired anhydride (1.25 equivalents) and the mixture

was heated to 150 °C in the microwave for 90 min. After LCMS confirmed the product, the rxn was added to EtOAc:NaHCO$_3$ (sat'd) (1:1) and the organic layer was separated, washed with Brine and dried (MgSO$_4$). After the organic layer was filtered and concentrated, the material was purified by LC purification (Gilson) or crystallization.

N-(3-Chloro-4-((1R,2S,3R,4S-bicyclo[2.2.1]hept-5-ene-1,3-dioxo-1*H*-isoindol-1-yl)phenyl) picolinamide (15f)

Following the general procedure, *N*-(3-Chloro-4-((1R,2S,3R,4S-bicyclo[2.2.1]hept-5-ene-1,3-dioxo-1*H*-isoindol-1-yl) phenyl)picolinamide was obtained (mixture of diastereomers). LCMS: R$_T$ = 1.367 min, >98% @ 254 nM, *m/z* = 394.0 [M + H]$^+$. ^{1}H NMR (400 MHz, MeOD) δ 8.81 (d, 1 H, *J* = 4.4 Hz), 8.40 (s, 1 H), 8.31-8.28 (m, 1 H), 8.20 (d, 1 H, *J* = 2.4 Hz), 7.84 (m, 1 H), 7.79 (d, 1 H, *J* = 2.4 Hz), 7.05 (d, 1 H, *J* = 8.4 Hz), 6.31 (s, 2 H), 3.61-3.56 (m, 2 H), 3.44-3.42 (m, 2 H), 1.79-1.76 (m, 1 H), 1.71-1.68 (m, 1 H). ^{13}C NMR (125 MHz, *d*-DMSO-d$_6$, mixture of diastereomers) δ 176.5, 176.4, 163.44, 163.42, 149.8, 149.7, 148.9, 140.7, 140.4, 138.7, 135.3, 135.0, 131.7, 131.2, 130.6, 127.7, 126.0, 125.6, 123.1, 121.34, 121.31, 120.2, 119.9, 52.4, 52.1, 46.9, 45.7, 45.3, 44.9. HRMS, calc'd for C$_{21}$H$_{17}$N$_3$O$_3$Cl [M + H]$^+$, 394.0958; found 394.0959.

N-(3-Chloro-4-(1,3-dioxo-2-azaspiro[4.5]decan-2-yl)phenyl)picolinamide (15j)

Following the general procedure, *N*-(3-chloro-4-(1,3-dioxo-2-azaspiro[4.5]decan-2-yl)phenyl)picolinamide was obtained. LCMS: R$_T$ = 1.439 min, >98% @ 254 nM, *m/z* = 398.2 [M + H]$^+$. ^{1}H NMR (400 MHz, *d*-DMSO-d$_6$) δ 11.01 (br s, 1 H), 8.76 (d, 1 H, *J* = 4.4 Hz), 8.24 (d, 1 H, *J* = 2.0 Hz), 8.17 (d, 1 H, *J* = 8.0 Hz), 8.08 (ddd, 1 H, *J* = 8.0, 8.0, 2.0 Hz), 7.99 (dd, 1 H, *J* = 8.4, 2.0 Hz), 7.70 (ddd, 1 H, *J* = 7.6, 4.8, 1.2 Hz), 7.39 (d, 1 H, *J* = 8.4 Hz), 2.86 (d, 1 H, *J* = 18.0 Hz), 2.78 (d, 1 H, *J* = 18.4 Hz), 1.77-1.60 (m, 7 H), 1.46-1.24 (m, 3 H). ^{13}C NMR (125 MHz, *d*-DMSO-d$_6$) δ 181.6, 175.1, 163.4, 149.7, 148.9, 140.7, 138.7, 131.7, 131.7, 131.1, 127.7, 125.8, 123.1, 121.3, 120.1, 45.3, 39.3, 34.0, 32.5, 25.1, 22.0, 21.9. HRMS, calc'd for C$_{21}$H$_{21}$N$_3$O$_3$Cl [M + H]$^+$, 398.1271; found 398.1271.

N-(3-Chloro-4-(2,5-dioxo-3-phenylpyrrolidin-1-yl)phenyl)picolinamide (15k)

Following the general procedure, *N*-(3-chloro-4-(2,5-dioxo-3-phenylpyrrolidin-1-yl)phenyl)picolinamide was obtained as a mixture of diastereomers (dr 2:1). *Major diastereomer:* LCMS: R$_T$ = 1.370 min, >98% @ 254 nM, *m/z* = 406.2 [M + H]$^+$. ^{1}H NMR (400 MHz, *d*-DMSO-d$_6$) δ 11.03 (br s, 1 H), 8.76 (d, 1 H, *J* = 4.8 Hz), 8.28 (d, 1 H, *J* = 2.4 Hz), 8.17 (d, 1 H, *J* = 8.0 Hz), 8.08 (ddd, 1 H, *J* = 7.6, 7.6, 1.6 Hz), 8.01 (dd, 1 H, *J* = 8.8, 2.4 Hz), 7.72-7.68 (m, 1 H), 7.52-7.30 (m, 6 H), 4.36 (dd, 1 H, *J* = 9.6, 5.2 Hz), 3.42 (dd, 1 H, *J* = 18.4, 9.6 Hz), 2.97 (dd, 1 H, *J* = 18.4, 5.2 Hz). ^{13}C NMR (125 MHz, *d*-DMSO-d$_6$, mixture of diastereomers) δ 177.1, 175.4, 175.1, 163.3, 149.5, 148.7, 140.8, 140.7, 138.9, 138.5, 137.9, 131.8, 131.7, 131.2, 130.9, 129.3, 129.1, 128.7, 128.4, 127.9, 127.7, 126.0, 125.9, 123.2, 121.4, 121.3, 120.24, 120.15, 46.5, 46.2, 37.7, 37.5. HRMS, calc'd for C$_{22}$H$_{17}$N$_3$O$_3$Cl [M + H]$^+$, 406.0958; found 406.0958.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003; 39:889–909. [PubMed: 12971891]

2. Schapira AHV. Neurobiology and treatment of Parkinson's disease. Trends Pharm. Sci. 2009; 30:41–47. [PubMed: 19042040]

3. Hefti FF. Parkinson's Disease. Drug Discovery for Nervous System Diseases. 2005:183–204.

4. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N.Y. Acad. Sci. 2003; 991:1–14. [PubMed: 12846969]

5. Warner TT, Schapira AHV. Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 2003; 53:S16–S25. [PubMed: 12666095]

6. Jellinger KA. Recent developments in the pathology of Parkinson's disease. J. Neural Trans. 2002; 62:347–376.

7. Parkinson J. An Essay on the Shaking Palsy. London, Sherwood, Neely and Jones. 1817

8. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Movement Disorders. 2008; 23:S497–S508. [PubMed: 18781671]

9. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G. Catechol-*O*-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenom and levodopa requirements in fluctuating Parkinsonian patients. Neurology. 1998; 50:S46–S53. [PubMed: 9591522]

10. Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Exp. Opin. Pharmacother. 2006; 7:1399–1407.

11. Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur. J. Neurol. 2002; 9:15–22. [PubMed: 12464117]

12. Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature Rev. Neuroscience. 2005; 6:787–798.

13. Conn PJ, Pin J-P. Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharmacol. Toxicol. 1997; 37:205–237. [PubMed: 9131252]

14. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug. Dis. 2009; 8:41–54.

15. Cuomo D, Martella G, Barabino E, Platania P, Vita D, Madeo G, Selvam C, Goudet C, Oueslati N, Pin J-P, Acher F, Pisani A, Beurrier C, Melon C, Kerkerian-LeGoff L, Gubellini P. Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J. Neurochem. 2009; 109:1096–1105. [PubMed: 19519781]

16. Lindsley CW, Niswender CM, Engers DW, Hopkins CR. Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinson's Disease. Curr. Top. Med. Chem. 2009; 9:949–963. [PubMed: 19754407]

17. Hopkins CR, Lindsley CW, Niswender CM. mGluR4 Positive Allosteric Modulation as Potential Treatment of Parkinson's Disease. Future Med. Chem. 2009; 1:501–513. [PubMed: 20161443]

18. Engers DW, Niswender CM, Weaver CD, Jadhav S, Menon UN, Zamorano R, Conn PJ, Lindsley CW, Hopkins CR. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J. Med. Chem. 2009; 52:4115–4118. [PubMed: 19469556]

19. Engers DW, Field JR, Le U, Zhou Y, Bolinger JD, Zamorano R, Blobaum AL, Jones CK, Jadhav S, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR. Discovery, synthesis, and structure-activity relationship development of a series of *N*-(4-acetamido)phenylpicolinamides as

positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu$_4$) with CNS exposure in rats. J. Med. Chem. 2011; 54:1106–1110. [PubMed: 21247167]

20. East SP, Bamford S, Dietz MGA, Eickmeier C, Flegg A, Ferger B, Gemkow MJ, Heilker R, Hengerer B, Kotey A, Loke P, Schänzle G, Schubert H-D, Scott J, Whittaker M, Williams M, Zawadzki P, Gerlach K. An orally bioavailable positive allosteric modulator of the mGlu$_4$ receptor with efficacy in an animal model of motor dysfunction. Bioorg. Med. Chem. Lett. 2010; 20:4901–4905. [PubMed: 20638279]

21. Compounds **1** (PHCCC), **2** (VU0155041), and **3** (VU0361737) are now available from TOCRIS bioscience (Cat. Nos. 1027, 3248, and 3707, respectively).

22. Niswender CM, Lebois EP, Luo Q, Kim K, Muchalski H, Yin H, Conn PJ, Lindsley CW. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-*d*]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg. Med. Chem. Lett. 2008; 18:5626–5630. [PubMed: 18793851]

23. Williams R, Niswender CM, Luo Q, Le U, Conn PJ, Lindsley CW. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg. Med. Chem. Lett. 2009; 19:962–966. [PubMed: 19097893]

24. Engers DW, Gentry PR, Williams R, Bolinger JD, Weaver CD, Menon UN, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR. Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu$_4$ positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Bioorg. Med. Chem. Lett. 2010; 20:5175–5178. [PubMed: 20667732]

25. Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ, Weaver CD. A novel assay of G$_{i/o}$-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Mol. Pharmacol. 2008; 73:1213–1224. [PubMed: 18171729]

26. Reynolds, IJ. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease. 6th International Meeting on Metabotropic Glutamate Receptors; 14 September – 19 September 2008; Taormina, Sicily, Italy. 2008.

27. Slee DH, Zhang X, Moorjani M, Lin E, Lanier MC, Chen Y, Rueter JK, Lechner SM, Markison S, Malany S, Joswig T, Santos M, Gross RS, Williams JP, Castro-Palomino JC, Cresp MI, Prat M, Gual S, Díaz J-L, Wen J, O'Brien Z, Saunders J. Identification of novel, water-soluble, 2-amino-*N*-pyrimidin-4-yl acetamides as A$_{2A}$ receptor antagonists with in vivo efficacy. J. Med. Chem. 2008; 51:400–406. [PubMed: 18189346]

28. VU0400195 (ML182) has been declared a probe via the Molecular Libraries Probe Production Centers Network (MLPCN) and is available through the network, see: http://mli.nih.gov/mli/.

Figure 1.
Structures of recently reported mGlu$_4$ PAMs.

Figure 2.
Structure of initial HTS hit.

Figure 10.
Reversal of haloperidol-induced catalepsy in rats by compounds **15f** after oral dosing.
Catalepsy was measured in haloperidol treated (0.75 mg/kg) rats after oral administration of
compound (0.1, 0.3, 1, 3, 10, 30 and 56.6 mg/kg) after 30 mins. An adenosine A_{2A}
antagonist from Neurocrine Biosciences[27] was used as a positive control at 56.6 mg/kg, po.

Scheme 1.
Synthesis of 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazol-2-yl)phenyl)carboxamides, **8a–l**.
[a] Reagents and conditions: (a) 1,2-benzenedisulfonyl dichloride, Et$_3$N, CH$_2$Cl$_2$; (b) 4.0 M
HCl/dioxane, 99% (2 steps); (c) RCOCl, CH$_2$Cl$_2$, DIEA, 49–87%; (d) RCO$_2$H, EDCI,
HOBt, dioxane/DMF, 27–74%. All library compounds were purified by mass-directed prep
LC with a purity of >95%.

Scheme 2.
Synthesis of *N*-4-(2,5-dioxopyrrolidin-1-yl)-phenylpicolinamides.'a
[a] Reagents and conditions: (a) Boc$_2$O, DMAP, THF, reflux, 99%; (b) Pd/C, EtOAc, H$_2$ (1 atm), rt; (c) Picolinoyl chloride HCl, CH$_2$Cl$_2$, pyridine, 84%; (d) 4.0 HCl/dioxane; (e) anhydride, toluene:AcOH (3:1), µW, 150 °C, 90 min. All library compounds were purified by mass-directed prep LC with a purity of >95%.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Table 1

Human mGlu4 potency and %GluMax response (as normalized to standard **1**) for selected western amide analogs.

Cmpd	R	hEC$_{50}$ (nM)^a	GluMax (%1)^a	tPSA	cLogP
8a	2-furan	226 ± 61	110.3 ± 5.8	109.9	1.77
8b	phenyl	402 ± 74	65 ± 1.5	100.6	2.60
8c	cyclohexyl	765 ± 133	48.3 ± 3.3	100.6	3.14
8d	2-pyridyl	136 ± 61	99.7 ± 0.9	113.0	2.19
8e	3-pyridyl	Inactive^b	27.7 ± 2.7	113.0	1.84
8f	4-pyridyl	Inactive^b	22.3 ± 1.9	113.0	1.84
8g	6-fluoro-2-pyridyl	1800 ± 1500	76.7 ± 8.1	113.0	2.42
8h	6-methoxy-2-pyridyl	Inactive^b	22.0 ± 1.2	122.2	2.64
8i	4-pyrimidine	179 ± 36	100.3 ± 4.9	125.3	1.41
8j	2-thiazole	353 ± 125	122.3 ± 5.9	113.0	2.05
8k	4-thiazole	104 ± 34	123 ± 1.2	113.0	2.05
8l	5-thiazole	Inactive^b	39.7 ± 0.3	113.0	2.05

^{a}EC$_{50}$ and maximal response when compared to glutamate (GluMax) are the average of at least three independent determinations performed in triplicate (Mean ± SEM). **1** is run as a control compound each day, and the maximal response generated in human mGlu4 CHO cells in the presence of mGlu4 PAMs varies slightly in each experiment. Therefore, data were further normalized to the relative **1** response obtained in each day's run.

^{b}Inactive compounds are defined as those in which the %GluMax did not surpass 2X the EC20 value for that day's run.

Table 2

Characteristics of previously reported mGlu$_4$ tool compounds from Vanderbilt University.

	2	3	8d

Parameter			
MW	262.7	386.2	414.5
TPSA	50.7	70.6	113.0
cLogP	2.80	2.74	2.19
hmGlu$_4$ EC$_{50}$ (nM)	240 ± 40	517 ± 57	136 ± 61
rmGlu$_4$ EC$_{50}$ (nM)	110 ± 30	570 ± 131	165 ± 1
rmGlu$_4$ CRC Fold Shift	35.3 ± 2.8	18.3 ± 1.3	5.2 ± 0.6
rat CL$_{HEP}$ (mL/min/kg)	65.5	27.3	ND
rPPB (%fu)	2.4	0.29	3.8
CYP (1A2, 2C9, 3A4, 2D6) μM	<0.1, >30, >30, >30	>30, 11.8, >30, 13.1	>30
mGlu selectivity	5.1 μM (5), 2.7 FS (8)	5.3 FS (7), 3.8 FS (8)	selective
B/P	4.1	1.04	0.085

Table 3

Human mGlu4 potency and efficacy (as normalized to standard **1**) for bis-sulfonamide scaffold modifications.

9a–d

Cmpd	X	Y	R2	hEC50 (nM)[a]	GluMax (%1)[a]	tPSA	cLogP
9a	CO	NH	2-F	1100 ± 424	67.7 ± 2.7	113	1.89
9b	CH2	NH	H	1800 ± 199	110.0 ± 6.2	95.9	1.54
9c	cyclopropyl	NH	H	6400 ± 750	62.7 ± 8.4	95.9	1.88
9d	NH	CO	H	Inactive[b]	30.7 ± 2.4	113	2.19

[a]EC50 and maximal response when compared to glutamate (GluMax) are the average of at least three independent determinations performed in triplicate (Mean ± SEM). **1** is run as a control compound each day, and the maximal response generated in human mGlu4 CHO cells in the presence of mGlu4 PAMs varies slightly in each experiment. Therefore, data were further normalized to the relative **1** response obtained in each day's run.

[b]Inactive compounds are defined as those in which the %GluMax did not surpass 2X the EC20 value for that day's run.

Table 4

Human mGlu$_4$ potency and efficacy (as normalized to standard **1**) for selected bis-sulfonamide replacements.

15a-l

Cmpd	R$_1$	R$_2$	hEC50 (nM)	GluMax (%1)	tPSA	cLogP
16		H	Inactive	25.0 ± 2.5	78.8	1.12
15a		Cl	6200 ± 1700	74.0 ± 4.5	78.8	0.69
15b		Cl	59.4 ± 7.9	103.7 ± 1.2	78.8	3.12
15c		Cl	41.9 ± 5.4	130.3 ± 3.4	78.8	3.86
15d		Cl	370 ± 23	107.0 ± 4.5	78.8	2.12

15a-l

Cmpd	R₁	R₂	hEC50 (nM)	GluMax (%1)	tPSA	cLogP
15e		Cl	1300 ± 180	90.0 ± 1.7	88.1	1.03
15f		Cl	291 ± 55	122.3 ± 1.5	78.8	1.91
15g		Cl	287 ± 62	120.3 ± 5.9	78.8	2.47
15h		Cl	435 ± 118	100.3 ± 2.9	78.8	0.96
15i		Cl	1400 ± 214	82.0 ± 3.5	78.8	1.73
15j		Cl	158 ± 20	78.7 ± 4.2	78.8	2.68

15a–l

Cmpd	R₁	R₂	hEC50 (nM)	GluMax (%1)	tPSA	cLogP
15k		Cl	674 ± 153	116.7 ± 8.3	78.8	2.45
15l		Cl	771 ± 126	123.7 ± 3.5	78.8	2.97

[a] EC50 and maximal response when compared to glutamate (GluMax) are the average of at least three independent determinations performed in triplicate (Mean ± SEM). 1 is run as a control compound each day, and the maximal response generated in human mGlu4 CHO cells in the presence of mGlu4 PAMs varies slightly in each experiment. Therefore, data were further normalized to the relative 1 response obtained in each day's run.

[b] Inactive compounds are defined as those in which the %GluMax did not surpass 2X the EC20 value for that day's run.

Table 5

Rat mGlu$_4$ receptor potency and efficacy (fold shift) data for selected compounds.

Cmpd	EC$_{50}$ (nM)[a]	GluMax[a]	Fold Shift
8d	165 ± 1	124.3 ± 3.6	5.2 ± 0.6
8i	242 ± 36	103.3 ± 3.2	3.3 ± 0.3
8j	201 ± 37	127.1 ± 4.5	4.7 ± 0.4
8k	105 ± 15	115.2 ± 2.3	7.3 ± 0.8
15b	66.8 ± 4	131.8 ± 3.9	23.6 ± 3.1
15c	34.9 ± 5.2	137.4 ± 3.2	83.0 ± 16.8
15d	645 ± 63	129.1 ± 2.8	8.3 ± 0.5
15f	376 ± 23	120.3 ± 3.2	11.2 ± 0.8
15g	246 ± 12	122.2 ± 4.5	5.2 ± 1.2
15h	686 ± 32	105.1 ± 0.1	5.5 ± 0.5
15j	397 ± 38	114.2 ± 1.5	4.8 ± 0.2
15k	491 ± 57	137.8 ± 2.0	12.1 ± 1.0
15l	536 ± 105	130.7 ± 3.9	16.7 ± 1.7

[a]EC$_{50}$ and maximal response when compared to glutamate (GluMax) are the average of at least three independent determinations performed in triplicate (Mean ± SEM).

Table 6

Predicted hepatic clearance, plasma protein binding, CYP450 inhibition, and mGlu selectivity values for selected compounds

	15f	15j	15k
Intrinsic Clearance (mL/min/kg)			
Human CL_{HEP}	19.7	19.4	19.9
Rat CL_{HEP}	53.0	66.7	32.6
Plasma Protein Binding (PPB)			
human (%fu)	4.1	0.62	0.02
rat (%fu)	3.2	0.5	0.17
BHB (rat, %fu)	7.6	1.7	1.4
CYP450 IC_{50} (μM)			
2C9	>30	>30	8.7
2D6	>30	>30	>30
3A4	>30	>30	>30
2C19	>30	>30	17.6
1A2	>30	>30	8.9
mGlu Selectivity[a]			
$mGlu_{1,2,3}$	Inactive[b]	Inactive[b]	Inactive[b]
$mGlu_5$	PAM, 2.1 FS	Inactive[b]	PAM 2.0 FS
$mGlu_6$	PAM, 3.1 FS	PAM, 2.1 FS	PAM, 5.8 FS
$mGlu_7$	PAM, 2.9 FS	Inactive[b]	Ago-PAM, 12.9 FS
$mGlu_8$	Inactive[b]	Inactive[b]	PAM, 2.1 FS

[a] Selectivity was assessed by incubating cells with either DMSO-matched vehicle or a 10 μM final concentration of compound in the presence of a full glutamate (or, in the case of mGlu7, L-AP4) concentration-response curve. FS = fold shift of the glutamate concentration-response curve. Cmpd **15f** showed weak potentiator activity on mGlu5, mGlu6 and mGlu7 (leftward shift of the glutamate concentration-response).

[b] Inactive compounds showed no ability to left-shift the glutamate response curve at 10 μM. No antagonist activity was noted for any compound at any receptor tested.

Table 7

Rat in vivo pharmacokinetic values for selected compounds

PK parameters (rat)	15f	15j	15k
IV (1 mg/kg)[a]			
CL (mL/min/kg)	36.9	48.3	5.4
$t_{1/2}$ (min)	40.4	93.8	329
MRT	493	57.2	109
Vss (L/kg)	18	5.5	0.58
AUC_{0-24} (ng*hr/mL)	454	346	3225
PO dose (10 mg/kg)[b]			
AUC_{0-24} (h*ng/mL)	4354	813	2685
C_{max} (ng/mL)	238	18.3	553
T_{max} (h)	0.62	7	0.5
%F	97	24.6	8.3

[a]10% EtOH, 80% PEG-400, 10% saline.

[b]10% Tween 80 in 0.5% methylcellulose.

Table 8

PO pharmacokinetic parameters of **15f**, (10 mg/kg, 10% Tween 80 in 0.5% methylcellulose).

15f

PK Parameter - AUC, 0 – 6 h[a]	nM·h
Systemic	858
HPV	848
Brain	800
AUC_{brain}/AUC_{sys}	0.93
AUC_{sys}/AUC_{HPV}	1.01

[b]PO dose, vehicle: 10 mg/kg, 10% Tween 80 in 0.5% methylcellulose